Compare Abeona Therapeutics Inc (ABEO) vs ARK Fintech Innovation ETF (ARKF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ARK Fintech Innovation ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while ARK Fintech Innovation ETF trades at $40.94. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | ARKF | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $58.82 |
52-Week Low | $4.17 | $36.14 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ARKF trades at $42.04, up 2.61% with strong technical momentum showing bullish signals across moving averages and oscillators. The stock faces resistance at $43-44 while finding support at $41-42 levels. Recent coverage highlights institutional interest in the fund's holdings, particularly in technology stocks favored by prominent investors.
The ETF's exposure to high-growth technology stocks positions it for potential upside, though elevated RSI levels suggest near-term consolidation risk. Investors face concentration risk in the fund's top holdings and market volatility sensitivity, requiring careful position sizing given the aggressive growth focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →
